Chronic Lymphocytic Leukemia (CLL) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

[Guest guest]

BlankChronic Lymphocytic Leukemia (CLL) Therapeutics - Pipeline Assessment and

Market Forecasts to 2017

The CLL Therapeutics Market is Forecast to Show High Growth Until 2017

FOR IMMEDIATE RELEASE

PRLog (Press Release) – Feb 15, 2011 – GlobalData estimates that the global CLL

therapeutics market was valued at $475m in 2010, and is forecast to grow at a

CAGR of 8% over the next seven years to reach $817m by 2017. This growth is

primarily attributed to the increase in the treatment usage patterns, such as

diseased population, treatment seeking population, diagnosis population,

prescription population, and the launch of monoclonal antibodies in the recent

past.

The CLL therapeutics market is relatively small compared to other cancers, yet

untapped opportunity exists for companies with better disease cures and

therapies with improved toxicities.

The current competition in the global CLL therapeutics market is moderate, as

the marketed products have been moderately successful in meeting demand. There

are currently four key drugs (Campath, Treanda, Arzerra and Rituxan) which are

moderately effective to meet the current unmet need. However there is a need for

effective and more tolerable therapies. Therefore opportunity exists for new

therapies to meet the unmet needs.

Monoclonal antibodies in the market and in clinical development will drive the

future CLL therapeutics market. Monoclonal antibodies have been the mainstay of

treatment and form the largest component of the market. Their use is expected to

increase in the future and many new monoclonal antibodies are in clinical

development, such as GA101, dacetuzumab, samalizumab, malituzumab and MOR208,

which if approved could further increase their dominance in the market.

GlobalData’s research indicates that the CLL pipeline landscape is moderate with

molecules in various phases of clinical development, defined as first-in-class,

me-too and product extensions. The first-in-class molecules have distinct

advantages over the currently used products in terms of better disease

management. In early studies, these drugs also display improvements in safety,

adverse events and efficacy profiles. They are expected to compete strongly with

currently used drugs, offering equal or better efficacies and safety profiles,

leading to increased patient and physician satisfaction.

GlobalData, the industry analysis specialist, has released its new report,

“Chronic Lymphocytic Leukemia (CLL) Therapeutics - Pipeline Assessment and

Market Forecasts to 2017”. The report is an essential source of information and

analysis on the global CLL therapeutics market. The report identifies the key

trends shaping and driving the global CLL therapeutics market. The report also

provides insights on the prevalent competitive landscape and the emerging

players expected to significantly alter the market positioning of the current

market leaders. Most importantly, the report provides valuable insights on the

pipeline products within the global CLL therapeutics sector. This report is

built using data and information sourced from proprietary databases, primary and

secondary research and in-house analysis by GlobalData’s team of industry

experts.